ACIU - AC Immune SA

-

$undefined

N/A

(N/A)

AC Immune SA NASDAQ:ACIU AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen.

Location: EPFL Innovation Park, Building B, Vaud, 1015, Switzerland | Website: www.acimmune.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

143.7M

Cash

157.9M

Avg Qtr Burn

N/A

Short % of Float

2.51%

Insider Ownership

21.84%

Institutional Own.

28.82%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PI-2620 Details
Alzheimer's disease, Neurological disorder

Phase 3

Data readout

Phase 2b

Data readout

ACI-7104.056 Details
Parkinson's disease

Phase 2

Data readout

Crenezumab Details
Alzheimer's disease, Neurological disorder

Phase 2

Update

Semorinemab Details
Neurological disorder, Alzheimer's disease

Phase 2

Update

ACI-24.060 (anti-Abeta vaccine) Details
Neurological disorder, Alzheimer's disease, Down Syndrome

Phase 1/2

Update

AC1-3024 Details
Neurological disorder

Failed

Discontinued